Walgreens Boots Alliance’s (WBA)’s chief executive officer Stefano Pessina has insisted that the firm is “not particularly worried” by online retail giant Amazon’s growing interest in the pharmacy market.
Walgreens Boots Alliance’s (WBA)’s chief executive officer Stefano Pessina has insisted that the firm is “not particularly worried” by online retail giant Amazon’s growing interest in the pharmacy market.
While Amazon’s recent acquisition of US online pharmacy PillPack (Generics bulletin,6July 2018, page 5) was a “declaration of intent”, Pessina acknowledged, PillPack – which delivers medications in pre-sorted dose packaging – was a “small company” that had been “up for sale for a while”
Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.
